Welcome to our dedicated page for Nanoviricides SEC filings (Ticker: NNVC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NanoViricides, Inc. (NNVC) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a NYSE American-listed biotechnology issuer. NanoViricides is a clinical stage company developing nanoviricide antiviral drug candidates, including its lead broad-spectrum candidate NV-387, and its filings offer insight into how it finances operations, governs the business, and advances its clinical and regulatory strategy.
Through Forms 10-K and 10-Q, investors can review NanoViricides’ discussion of research and development activities, risk factors related to clinical-stage antiviral programs, licensing arrangements with TheraCour Pharma, Inc., and details of its nanomedicine platform. These periodic reports also describe the company’s cash position, use of proceeds from offerings, and its assessment of the lengthy, capital-intensive path required to bring pharmaceutical products from early research to potential approval.
Current reports on Form 8-K capture material events such as securities purchase agreements, registered direct offerings, concurrent private placements, and related warrant issuances. For example, a recent Form 8-K describes a securities purchase agreement with an institutional investor, including pre-funded warrants and Series A and Series B common stock purchase warrants, as well as a placement agency agreement and lock-up arrangements with directors and executive officers. Other 8-K filings cover topics like annual shareholder meeting results, executive employment agreement extensions, and amendments to a shareholder-provided line of credit.
Definitive proxy statements on Schedule 14A detail matters submitted to shareholders, including director elections, advisory votes on executive compensation, and ratification of independent auditors. They also describe voting rights associated with common stock and Series A preferred stock. On Stock Titan, these filings are paired with AI-powered summaries that highlight key terms, capital structure changes, and governance decisions, helping users quickly interpret complex documents while retaining the ability to review the full text filed with the SEC.
NanoViricides, Inc. is presenting a definitive proxy for a shareholder meeting that includes the election of one Class I director and discusses director and executive compensation principles. The election requires a plurality vote with only "For" or "Withheld" votes counting and broker non-votes having no effect. The document emphasizes tying executive pay to company performance through annual bonuses and long-term awards that consider financial and individual goals and corporate values. It also discloses non-employee director equity holdings: Dr. Jawadekar 41,536, Mr. Rokita 41,009, and Mr. Zucker 39,786.
NanoViricides, Inc. filed an 8-K disclosing several exhibit-level agreements that were furnished with the report. The filing lists extensions of employment agreements for Anil Diwan and Meeta Vyas, with Meeta Vyas’s extension effective
The filing provides the existence and dates of these agreements but contains no financial tables, amounts, or detailed terms in the provided text. The exhibits indicate personnel continuity at the executive level and new or amended financing arrangements secured on
NanoViricides, Inc. (NNVC) is a development-stage biopharmaceutical company focused on nanoviricide antiviral drug candidates and has no commercial products or revenue. The filing discloses a net loss of approximately $9.5 million and net cash used in operating activities of about $8.5 million for the year, cash and cash equivalents of approximately $1.6 million at June 30, 2025, and additional ATM equity sales of about $1.25 million through September 24, 2025. Management states substantial doubt about the company’s ability to continue as a going concern absent additional financing and available credit under a $3.0 million line of credit. The company reports ongoing preclinical and clinical activities for NV-387 (multiple Indications including MPox, ARI/SARI, RSV and COVID formulations), license arrangements with milestone and royalty obligations, and reliance on third-party collaborators for trials, manufacturing and commercialization.